“Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s22. https://doi.org/10.25251/skin.1.supp.21.